Unknown

Dataset Information

0

Low Prevalence of Hepatitis B Vaccination Among Patients Receiving Medical Care for HIV Infection in the United States, 2009 to 2012.


ABSTRACT: Background:Persons with HIV infection are at increased risk for hepatitis B virus infection. In 2016, the World Health Organization resolved to eliminate hepatitis B as a public health threat by 2030. Objective:To estimate the prevalence of hepatitis B vaccination among U.S. patients receiving medical care for HIV infection ("HIV patients"). Design:Nationally representative cross-sectional survey. Setting:United States. Participants:18 089 adults receiving HIV medical care who participated in the Medical Monitoring Project during 2009 to 2012. Measurements:Primary outcomes were prevalence of 1) no documentation of hepatitis B vaccination or laboratory evidence of immunity or infection (candidates to initiate vaccination), and 2) initiation of vaccination among candidates, defined as documentation of at least 1 vaccine dose in a 1-year surveillance period during which patients received ongoing HIV medical care. Results:At the beginning of the surveillance period, 44.2% (95% CI, 42.2% to 46.2%) of U.S. HIV patients were candidates to initiate vaccination. By the end of the surveillance period, 9.6% (CI, 8.4% to 10.8%) of candidates were vaccinated, 7.5% (CI, 6.4% to 8.6%) had no documented vaccination but had documented infection or immunity, and 82.9% (CI, 81.1% to 84.7%) remained candidates. Among patients at facilities funded by the Ryan White HIV/AIDS Program (RWHAP), 12.5% (CI, 11.1% to 13.9%) were vaccinated during the surveillance period versus 3.7% (CI, 2.6% to 4.7%) at facilities not funded by RWHAP. At the end of surveillance, 36.7% (CI, 34.4% to 38.9%) of HIV patients were candidates to initiate vaccination. Limitation:The study was not designed to describe vaccine series completion or actual prevalence of immunity. Conclusion:More than one third of U.S. HIV patients had missed opportunities to initiate hepatitis B vaccination. Meeting goals for hepatitis B elimination will require increased vaccination of HIV patients in all practice settings, particularly at facilities not funded by RWHAP. Primary Funding Source:Centers for Disease Control and Prevention.

SUBMITTER: Weiser J 

PROVIDER: S-EPMC5820114 | biostudies-literature | 2018 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Low Prevalence of Hepatitis B Vaccination Among Patients Receiving Medical Care for HIV Infection in the United States, 2009 to 2012.

Weiser John J   Perez Alejandro A   Bradley Heather H   King Hope H   Shouse R Luke RL  

Annals of internal medicine 20171226 4


<h4>Background</h4>Persons with HIV infection are at increased risk for hepatitis B virus infection. In 2016, the World Health Organization resolved to eliminate hepatitis B as a public health threat by 2030.<h4>Objective</h4>To estimate the prevalence of hepatitis B vaccination among U.S. patients receiving medical care for HIV infection ("HIV patients").<h4>Design</h4>Nationally representative cross-sectional survey.<h4>Setting</h4>United States.<h4>Participants</h4>18 089 adults receiving HIV  ...[more]

Similar Datasets

| S-EPMC3890334 | biostudies-literature
| S-EPMC6711156 | biostudies-literature
| S-EPMC3375879 | biostudies-literature
| S-EPMC3149556 | biostudies-literature
| S-EPMC4521706 | biostudies-literature
| S-EPMC3544875 | biostudies-other
| S-EPMC4004641 | biostudies-literature
| S-EPMC4061532 | biostudies-literature
| S-EPMC4574953 | biostudies-literature
| S-EPMC4770258 | biostudies-literature